keyword
https://read.qxmd.com/read/38590373/characterization-of-brain-development-with-neuroimaging-in-a-female-mouse-model-of-chemotherapy-treatment-of-acute-lymphoblastic-leukemia
#1
JOURNAL ARTICLE
Kellen Gandy, Timothy R Koscik, Tyler Alexander, Jeffrey D Steinberg, Kevin R Krull, Ellen van der Plas
BACKGROUND: Survivors of pediatric acute lymphoblastic leukemia (ALL) exhibit abnormal neurocognitive outcomes that are possibly due to exposures to neurotoxic chemotherapy agents. This study aimed to determine the feasibility of characterizing long-term neuroanatomical changes with in vivo neuroimaging in a preclinical model of treatment for ALL. METHODS: Female mice (C57BL/6) were randomly assigned to a saline control group (n=10) or a treatment group (n=10) that received intrathecal methotrexate and oral dexamethasone (IT-MTX + DEX)...
March 27, 2024: Translational Pediatrics
https://read.qxmd.com/read/38539543/cumulative-dosage-of-intrathecal-chemotherapy-agents-predicts-white-matter-integrity-in-long-term-survivors-of-acute-lymphoblastic-leukemia-a-petale-study
#2
JOURNAL ARTICLE
Julie Laniel, Serge Sultan, Daniel Sinnett, Caroline Laverdière, Maja Krajinovic, Philippe Robaey, Luc Duong, Sarah Lippé
Acute lymphoblastic leukemia (ALL) stands as the most prevalent form of pediatric cancer in North America, with a current five-year survival rate of 85%. While more children achieved ALL remission and transition into adulthood, the prevalence of long-term treatment-related effects, especially neurocognitive sequelae, remains significant. This study pursues two objectives. Firstly, it investigates if Magnetization Transfer Ratio (MTR), a method assessing myelin integrity, is sensitive to white matter (WM) microstructural changes in long-term ALL survivors and whether these relate to cognitive impairments...
March 19, 2024: Cancers
https://read.qxmd.com/read/38508620/rituximab-combined-anthracycline-free-chemotherapy-in-newly-diagnosed-paediatric-and-adolescent-patients-with-non-high-risk-aggressive-mature-b-cell-lymphoma-protocol-for-a-single-arm-open-label-multicentre-phase-ii-study-the-japan-children-s-cancer-group-multicentre
#3
JOURNAL ARTICLE
Masahiro Sekimizu, Reiji Fukano, Yuhki Koga, Tetsuo Mitsui, Naoto Fujita, Takeshi Mori, Daiki Hori, Makito Tanaka, Kentaro Ohki, Hideto Iwafuchi, Atsuko Nakazawa, Tetsuya Mori, Ryoji Kobayashi, Hiroya Hashimoto, Akiko M Saito, Michi Kamei
INTRODUCTION: Children and adolescents with mature B cell non-Hodgkin lymphoma (B-NHL) are treated with short-intensive chemotherapy. The burden of short-term and long-term toxicity is highly relative to its high cure rate in good-risk patients. Although the addition of rituximab to standard lymphome Malin B (LMB) chemotherapy markedly prolongs event-free survival and overall survival in high-risk patients, the benefit of rituximab in good-risk patients remains to be elucidated. This clinical trial will examine whether the addition of rituximab eliminates anthracyclines in good-risk patients without compromising treatment outcomes...
March 19, 2024: BMJ Open
https://read.qxmd.com/read/38489712/postpartum-choriocarcinoma-a-rare-cause-of-delayed-postpartum-hemorrhage-four-case-reports-and-literature-review
#4
JOURNAL ARTICLE
Guan-Lin Dai, Fu-Rong Tang, Yu Ma, Dan-Qing Wang
BACKGROUND: Delayed postpartum hemorrhage is rare, with an incidence of 0.5% to 2.0% in all pregnancies. The most important causes are placental remnants, infections, and placental bed subinvolution. Postpartum choriocarcinoma, a highly malignant complication of pregnancy, is a rare condition that can be easily misdiagnosed as other common causes, such as gestational remnants, and delays the diagnosis. METHODS: Four patients visited our clinic complaining of delayed postpartum hemorrhage, combined with respiratory and neurological symptoms in 2 cases...
March 15, 2024: Medicine (Baltimore)
https://read.qxmd.com/read/38466670/burkitt-lymphoma-the-effect-of-age-sex-and-delay-to-diagnosis-on-treatment-completion-and-outcome-of-treatment-in-934-patients-in-cameroon
#5
JOURNAL ARTICLE
Peter Bernard Hesseling, Glenn Mbah Afungchwi, Bernard Wirndzem Njodzeka, Paul Wharin, Francine Nicole Kouya, Mariana Kruger
INTRODUCTION: The role of age and sex in the presentation and outcome of endemic Burkitt lymphoma (BL) has not been studied recently. This study analysed these factors in 934 patients with BL who had received cyclophosphamide and intrathecal methotrexate as treatment. METHODS: Records of 934 children diagnosed with BL from 2004 to 2015 were obtained from our Paediatric Oncology Networked Database (POND) cancer registry. Age at diagnosis, sex, disease stage, time to diagnosis, delay in diagnosis, completion of treatment, rate of abandonment, and one-year survival rates were recorded and statistically analysed...
2024: PloS One
https://read.qxmd.com/read/38445428/cerebral-venous-thrombosis-after-first-methotrexate-administration-by-lumbar-puncture-in-a-patient-with-large-b-cell-lymphoma
#6
JOURNAL ARTICLE
Aicha Ben Kahla, Olfa Kassar, Khadija Moalla, Yosra Fakhfakh, Yosr Hentati, Moez Elloumi
Cerebral venous thrombosis is a rare consequence of lumbar punctures for intrathecal therapy. We report a patient treated for diffuse large B cell lymphoma with cerebral venous thrombosis after intrathecal Methotrexate administration. In this patient, intrathecal treatment was discontinued and he was successfully treated with high-dose low-molecular-weight heparin subcutaneously. Haematologist must be aware about neurological symptoms of cerebral venous thrombosis as a complication of lumbar puncture especially among patients with high coagulopathy state...
July 5, 2023: La Tunisie Médicale
https://read.qxmd.com/read/38435502/relapsed-isolated-cns-lymphoma-treated-with-radiotherapy-and-intrathecal-methotrexate-followed-by-high-dose-intravenous-methotrexate-rituximab-and-temozolomide-a-case-report
#7
Ikhwan Rinaldi, Abdul Muthalib, Soehartati Gondhowiardjo, Tjondro Setiawan, Andhika Gunawan, Nelly Susanto, Lingga Magdalena, Kevin Winston, Ashila Disamantiji, Bintang Wirawan
KEY CLINICAL MESSAGE: Optimized treatments for relapsed isolated CNS lymphoma (RI-SCNSL) remains under investigation. Temozolomide combination-based therapy, which is often used in glioblastoma may be used as potential treatment in RI-SCNSL. ABSTRACT: One of the most common types of non-Hodgkin lymphoma (NHL) is diffuse large B-cell lymphoma (DLBCL). Despite advances in treatment, relapsed isolated CNS lymphoma (RI-SCNSL) from DLBCL remains an issue. The optimal approach in RI-SCNSL remains an area of active investigation as currently there is no high level of evidence for the treatments due to lack of randomized studies...
March 2024: Clinical Case Reports
https://read.qxmd.com/read/38417873/successful-treatment-of-isolated-central-nervous-system-recurrence-of-primary-testicular-lymphoma-by-autologous-stem-cell-transplantation-using-a-conditioning-regimen-of-thiotepa-and-busulfan
#8
JOURNAL ARTICLE
Yasuhiro Tanaka, Tomomi Sakai, Hiroko Tsunemine, Tomoo Ito, Nobuyoshi Arima
Primary testicular lymphoma (PTL) frequently relapses in the central nervous system (CNS) despite prophylactic intrathecal chemotherapy, and the outcome for CNS recurrence of PTL is very poor. We report a case of isolated CNS recurrence of bilateral PTL. Our patient achieved complete response (CR) after rituximab-combination chemotherapy for PTL. Approximately five years later, isolated CNS recurrence of PTL occurred. Our patient achieved CR again after high-dose methotrexate therapy and autologous stem cell transplantation (ASCT) with a conditioning regimen of thiotepa and busulfan as a consolidation therapy...
February 28, 2024: Journal of Clinical and Experimental Hematopathology: JCEH
https://read.qxmd.com/read/38416167/ommaya-reservoir-use-in-pediatric-all-and-nhl-a-review-at-st-jude-children-s-research-hospital
#9
JOURNAL ARTICLE
Alyssa Gaietto, John C Panetta, Jennifer L Pauley, Mary V Relling, Raul Ribeiro, Matthew J Ehrhardt, Ching-Hon Pui, Hiroto Inaba, Hope D Swanson
PURPOSE: The intraventricular route of chemotherapy administration, via an Ommaya Reservoir (OmR) improves drug distribution in the central nervous system (CNS) compared to the more commonly used intrathecal administration. We retrospectively reviewed our experience with intraventricular chemotherapy, focused on methotrexate, in patients with Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL). METHODS: Twenty-four patients (aged 7 days - 22.2 years) with 26 OmR placements were identified for a total of 25,009 OmR days between 1990 and 2019...
February 28, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38377785/efficacy-and-safety-of-intrathecal-pemetrexed-for-tki-failed-leptomeningeal-metastases-from-egfr-nsclc-an-expanded-single-arm-phase-ii-clinical-trial
#10
JOURNAL ARTICLE
C Fan, Z Jiang, C Teng, X Song, L Li, W Shen, Q Jiang, D Huang, Y Lv, L Du, G Wang, Y Hu, S Man, Z Zhang, N Gao, F Wang, T Shi, T Xin
BACKGROUND: This study aimed to evaluate the efficacy and safety of intrathecal pemetrexed (IP) for treating patients with leptomeningeal metastases (LM) from non-small-cell lung cancer (NSCLC) who progressed from epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment in an expanded, prospective, single-arm, phase II clinical study (ChiCTR1800016615). PATIENTS AND METHODS: Patients with confirmed NSCLC-LM who progressed from TKI received IP (50 mg, day 1/day 5 for 1 week, then every 3 weeks for four cycles, and then once monthly) until disease progression or intolerance...
February 19, 2024: ESMO Open
https://read.qxmd.com/read/38371059/management-of-acute-lymphoblastic-leukemia-during-pregnancy-a-case-report-and-review-of-the-literature
#11
Saleha Nadeem, Ehsan Elahi, Imran Iftikhar, Sobia Umar, Bushra Ahsan, Usman Ahmad, Syed W Bokhari
Acute lymphoblastic leukemia (ALL) during pregnancy necessitates treatment with high-dose chemotherapy, which can threaten the lives of both the mother and fetus. The aim of the treatment not only focuses on selecting and administering optimal chemotherapy with appropriate doses to the mother but also reflects the crucial understanding of the fetal gestational age at the time of administration of chemotherapy to minimize fetal exposure. We describe the case of a 19-year-old patient diagnosed with ALL at 29 weeks gestation...
January 2024: Curēus
https://read.qxmd.com/read/38339976/the-treatment-of-burkitt-lymphoma-with-the-berlin-frankfurt-m%C3%A3-nster-protocol-with-rituximab-and-consolidative-autologous-transplantation
#12
JOURNAL ARTICLE
Alessandro Broccoli, Lisa Argnani, Gabriele Gugliotta, Cinzia Pellegrini, Beatrice Casadei, Gianmarco Bagnato, Marianna Gentilini, Vittorio Stefoni, Pier Luigi Zinzani
INTRODUCTION: Intensive treatment approaches are required for adult patients with Burkitt lymphoma (BL), although an univocal standard of care still does not exist. The use of frontline autologous stem cells transplantation (ASCT) is debated. PATIENTS AND METHODS: Between 2004 and 2020, 50 patients with BL were treated with the Berlin-Frankfurt-Münster (BFM). Treatment plan consisted of 3 blocks, A (ifosfamide, vincristine, methotrexate, etoposide, and cytarabine), B (vincristine, cyclophosphamide, methotrexate, and doxorubicin), and C (vindesine, methotrexate, etoposide, and cytarabine), each repeated twice, every 28 days...
February 10, 2024: Oncologist
https://read.qxmd.com/read/38334635/blastic-plasmacytoid-dendritic-cell-neoplasm-a-comprehensive-review-of-the-disease-central-nervous-system-presentations-and-treatment-strategies
#13
REVIEW
Shefali Mehra, Justin Taylor
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy with poor outcomes. The World Health Organization (WHO) redefined BDCN as a distinct disease entity in 2016. BPDCN arises from plasmacytoid dendritic cells, manifesting primarily in the skin, bone marrow, and lymph nodes, occasionally involving the central nervous system (CNS). This presents challenges in diagnosis and treatment, with CNS involvement often overlooked in standard diagnostic workups due to BPDCN's rarity and patients often being neurologically asymptomatic at diagnosis...
January 28, 2024: Cells
https://read.qxmd.com/read/38323945/predictive-factors-associated-with-radiation-myelopathy-in-pediatric-patients-with-cancer-a-pentec-comprehensive-review
#14
JOURNAL ARTICLE
Benjamin T Cooper, Charles S Mayo, Michael T Milano, Arthur J Olch, Cheongeun Oh, Gesina F Keating, Anneka Hallstrom, Louis S Constine, Nadia N Laack
PURPOSE: Radiation myelitis (RM) is a rare complication of radiation therapy (RT). The Pediatric Normal Tissue Effects in the Clinic spinal cord task force aimed to identify RT dose effects and assess risk factors for RM in children. Through systematic review, we analyzed RT dose, fraction size, latency between completion of RT and toxicity, chemotherapy use, age when irradiated, and sex. METHODS AND MATERIALS: We conducted literature searches of peer-reviewed manuscripts published from 1964 to June 2017 evaluating RM among children...
February 6, 2024: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/38312196/a-retrospective-cohort-study-to-evaluate-the-outcomes-of-hiv-associated-high-grade-b-cell-non-hodgkin-lymphoma-nhl-treated-with-dose-adjusted-epoch-r-regimen
#15
JOURNAL ARTICLE
Jayashree Thorat, Manju Sengar, Raajit Chanana, Akhil Kapoor, Ajay Singh, Avinash Bonda, Hari Menon, Bhausaheb Bagal, Siddharth Laskar, Nehal Khanna, Jayant Shastri Goda, Epari Sridhar, Sumeet Gujral, Archi Agarwal, Sheela Sawant, Anuprita Daddi, Tanuja Shet, Netra Ghandade, Hasmukh Jain
UNLABELLED: High-grade B-cell NHL's are more common in seropositive patients. They are biologically different from their seronegative counterparts. We report our analysis on our cohort of patients who were treated with DA-EPOCH(+/-R). We retrospectively analyzed treatment-naïve HIV-associated High-grade B-cell NHL patients (aged ≥ 18) treated with DA-EPOCH(+/-R) regimen from 2011 to 2015. Descriptive statistics were summarized with median and range; survival outcomes were analyzed with Kaplan-Meier method...
January 2024: Indian Journal of Hematology & Blood Transfusion
https://read.qxmd.com/read/38294637/intrathecal-chemotherapy-for-leptomeningeal-disease-in-high-grade-gliomas-a-systematic-review
#16
REVIEW
Eric Singh, Muhammet Enes Gurses, Meredith C Costello, Chandler Berke, Victor M Lu, Lekhaj Daggubati, Ricardo J Komotar, Michael E Ivan, Ashish H Shah
BACKGROUND: Leptomeningeal disease (LMD) secondary to high grade glioma (HGG), such as glioblastoma (GBM), are characterized by the spread of tumor cells to the leptomeninges which further complicates treatment approaches. Intrathecal (IT) chemotherapy has surfaced as a potential strategy to bypass the blood-brain barrier and address the challenges posed by disseminated disease. Here, we present a review of the safety and efficacy of IT chemotherapy in the treatment of LMD secondary to HGG...
March 2024: Journal of Neuro-oncology
https://read.qxmd.com/read/38289997/mechanistic-modeling-of-intrathecal-chemotherapy-pharmacokinetics-in-the-human-central-nervous-system
#17
JOURNAL ARTICLE
Jing Li, Andrew Wu, Seongho Kim
PURPOSE: The pharmacokinetics of intrathecally administered antibody or small-molecule drugs in the human central nervous system (CNS) remains poorly understood. This study aimed to provide mechanistic and quantitative perspectives on the CNS pharmacokinetics of intrathecal chemotherapy, by using physiologically based pharmacokinetic (PBPK) modeling approach. EXPERIMENTAL DESIGN: A novel CNS PBPK model platform was developed and verified, which accounted for the human CNS general anatomy and physiological processes governing drug distribution and disposition...
January 30, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38233702/comparison-of-standardized-prophylactic-high-dose-and-intrathecal-methotrexate-for-dlbcl-with-a-high-risk-of-cns-relapse
#18
MULTICENTER STUDY
Masahiro Akimoto, Takuya Miyazaki, Hiroyuki Takahashi, Yusuke Saigusa, Takaaki Takeda, Yuto Hibino, Mayumi Tokunaga, Takuma Ohashi, Ayako Matsumura, Haruka Teshigawara, Taisei Suzuki, Hiroshi Teranaka, Yuki Nakajima, Kenji Matsumoto, Chizuko Hashimoto, Katsumichi Fujimaki, Hiroyuki Fujita, Rika Sakai, Shin Fujisawa, Hideaki Nakajima
The efficacy of high-dose methotrexate (HD-MTX) for central nervous system (CNS) relapse prophylaxis in patients with high-risk diffuse large B-cell lymphoma (DLBCL) is controversial. We compared the prophylactic effects of HD-MTX and intrathecal methotrexate (IT-MTX) on CNS relapse in high-risk DLBCL, in a multicenter retrospective study. A total of 132 patients with DLBCL at high risk of CNS relapse who received frontline chemotherapy and IT-MTX from 2003 to 2013 (n = 34) or HD-MTX from 2014 to 2020 (n = 98) were included...
February 2024: International Journal of Hematology
https://read.qxmd.com/read/38205044/intrathecal-therapy-options-for-meningeal-carcinomatosis
#19
JOURNAL ARTICLE
Madeleine Marowsky, Volkmar Müller, Barbara Schmalfeldt, Kerstin Riecke, Isabell Witzel, Elena Laakmann
Around 5 percent of all patients with metastatic breast cancer go on to develop distant metastases in the meninges, also known as meningeal carcinomatosis. The median survival of these patients is between 3.5 and 4.5 months. Current treatment approaches are based on radiotherapy, systemic and intrathecal therapy. Methotrexate, liposomal cytarabine and trastuzumab are the most common substances used for intrathecal therapy. The aim of this review was to provide an overview of these intrathecal therapy options for meningeal carcinomatosis...
January 2024: Geburtshilfe und Frauenheilkunde
https://read.qxmd.com/read/38195323/soho-state-of-the-art-updates-and-next-questions-next-questions-acute-lymphoblastic-leukemia
#20
REVIEW
Jayastu Senapati, Hagop Kantarjian, Fadi G Haddad, Nicholas J Short, Mary Alma Welch, Nitin Jain, Elias Jabbour
The integration of immune and targeted therapies into the treatment of acute lymphoblastic leukemia (ALL) has significantly improved outcomes, reduced the intensity and duration of chemotherapy, and the reliance on allogeneic stem cell transplantation (SCT). In younger patients with Philadelphia chromosome (Ph)-negative ALL, treatment with Hyper-CVAD and blinatumomab +/- inotuzumab has improved the 3-year overall survival (OS) to above 85%. In older patients, using less intensive chemotherapy (mini-Hyper-CVD) in combination with inotuzumab and blinatumomab has improved the 5-year OS rate to 50%...
January 8, 2024: Clinical Lymphoma, Myeloma & Leukemia
keyword
keyword
111629
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.